2,6-dimethylcyclohexylamine hydrochloride | 192703-30-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2,6-dimethylcyclohexylamine hydrochloride
• 英文别名: 2,6-Dimethylcyclohexan-1-amine hydrochloride；2,6-dimethylcyclohexan-1-amine;hydrochloride
• CAS: 192703-30-3
• 化学式: C₈H₁₇N*ClH
• mdl: MFCD09971633
• 分子量: 163.691
• InChiKey: BSUFNVVBXFPPCY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (R)-5-bromo-2-chloro-4-(tetrahydrofuran-3-yloxy)pyrimidine 、 2,6-dimethylcyclohexylamine hydrochloride 生成 4-((R)-tetrahydrofuran-3-yloxy)-5-bromo-N-(2,6-dimethylcyclohexyl)pyrimidin-2-amine
  参考文献：
  名称：

  Pyrimidine compounds and methods of making and using same

  摘要：

  本文揭示了嘧啶基化合物，预计其是囊性纤维化跨膜调节蛋白（CFTR）的调节剂，并提供制备和使用它们的方法。还提供了制药组合物和治疗与囊性纤维化跨膜调节蛋白相关的疾病的方法，例如呼吸道炎症，囊性纤维化等。

  公开号：

  US08513242B2

文献信息

• Novel guanidinobenzamides
  申请人：——

  公开号：US20020137939A1

  公开（公告）日：2002-09-26

  Compounds of formula IA and IB are new 1 where the variables R 1 through R 10 have the values set forth herein. Such compounds have use in treating diseases such as obesity and type II diabetes, and may be provided as pharmaceutical formulations in conjunction with a pharmaceutically acceptable carrier.

  公式IA和IB的化合物是新的，其中变量R1到R10具有以下数值。这些化合物在治疗肥胖和2型糖尿病等疾病方面具有用途，并可作为与药学上可接受的载体结合的药物制剂提供。
• 3-pyrazolecarboxamide derivatives having cannabinoid receptor affinity
  申请人：Sanofi

  公开号：US05925768A1

  公开（公告）日：1999-07-20

  The present invention relates to compounds of the formula ##STR1## in which: X.sub.1 is a group --NR.sub.1 R.sub.2 or a group --OR.sub.2 ; g.sub.2, g.sub.3, g.sub.4, g.sub.5, g.sub.6 and w.sub.2, w.sub.3, w.sub.4, w.sub.5, w.sub.6 are identical or different and are each independently hydrogen, a halogen atom, a (C.sub.1 -C.sub.4)alkyl, a (C.sub.1 -C.sub.4)alkoxy, a trifluoromethyl, a nitro or a (C.sub.1 -C.sub.4)alkylthio, with the proviso that at least one of the substituents g.sub.2, g.sub.3, g.sub.4, g.sub.5, g.sub.6 and at least one of the substituents w.sub.2, w.sub.3, w.sub.4, w.sub.5, w.sub.6 are other than hydrogen; R.sub.1 is hydrogen or a (C.sub.1 -C.sub.4)alkyl; R.sub.2 is a non-aromatic (C.sub.3 -C.sub.15)carbocyclic radical which is unsubstituted or monosubstituted or polysubstituted by a substituent selected from a halogen atom, a (C.sub.1 -C.sub.4)alkyl and a (C.sub.1 -C.sub.4)alkoxy; R.sub.3 is hydrogen or a group --CH.sub.2 R.sub.6 ; and R.sub.4 and R.sub.5 are each independently a hydrogen, a (C.sub.1 -C.sub.4)alkyl or a trifluoromethyl; or else R.sub.4 is hydrogen and R.sub.5 and w.sub.6 together constitute an ethylene or trimethylene radical; and R.sub.6 is hydrogen, a (C.sub.1 -C.sub.4)alkyl, a fluorine, a hydroxyl, a (C.sub.1 -C.sub.5)alkoxy, a (C.sub.1 -C.sub.5)alkylthio, a hydroxy(C.sub.1 -C.sub.5)alkoxy, a cyano, a (C.sub.1 -C.sub.5)alkylsulfinyl or a (C.sub.1 -C.sub.5)alkylsulfonyl with the proviso that when the substituents g.sub.2, g.sub.3, g.sub.4, g.sub.5 and/or g.sub.6 are a (C.sub.1 -C.sub.4)alkyl R.sub.6 is only hydrogen; to a process for their preparation and to the pharmaceutical compositions in which they are present. These compounds have a good affinity for the peripheral cannabinoid receptors.

  本发明涉及以下公式的化合物：##STR1## 其中：X.sub.1是一个基团--NR.sub.1 R.sub.2或一个基团--OR.sub.2；g.sub.2，g.sub.3，g.sub.4，g.sub.5，g.sub.6和w.sub.2，w.sub.3，w.sub.4，w.sub.5，w.sub.6相同或不同，每个独立地为氢、卤素原子、(C.sub.1-C.sub.4)烷基、(C.sub.1-C.sub.4)烷氧基、三氟甲基、硝基或(C.sub.1-C.sub.4)烷基硫醇，但要求至少有一个取代基g.sub.2，g.sub.3，g.sub.4，g.sub.5，g.sub.6和至少有一个取代基w.sub.2，w.sub.3，w.sub.4，w.sub.5，w.sub.6不是氢；R.sub.1是氢或(C.sub.1-C.sub.4)烷基；R.sub.2是非芳香性(C.sub.3-C.sub.15)碳环基，未取代或单取代或多取代，所述取代基选自卤素原子、(C.sub.1-C.sub.4)烷基和(C.sub.1-C.sub.4)烷氧基；R.sub.3是氢或基团--CH.sub.2 R.sub.6；R.sub.4和R.sub.5各自独立地为氢、(C.sub.1-C.sub.4)烷基或三氟甲基；否则，R.sub.4是氢，而R.sub.5和w.sub.6共同构成乙烯或三亚甲基基团；R.sub.6是氢、(C.sub.1-C.sub.4)烷基、氟、羟基、(C.sub.1-C.sub.5)烷氧基、(C.sub.1-C.sub.5)烷硫基、羟基(C.sub.1-C.sub.5)烷氧基、氰基、(C.sub.1-C.sub.5)烷基亚砜或(C.sub.1-C.sub.5)烷基磺酰基，但要求当取代基g.sub.2，g.sub.3，g.sub.4，g.sub.5和/或g.sub.6为(C.sub.1-C.sub.4)烷基时，R.sub.6仅为氢；以及制备它们的过程和它们存在的药物组合物。这些化合物具有与周围的大麻素受体良好的亲和力。
• Pyrimidine Compounds and Methods of Making and Using Same
  申请人：Chiang Phoebe

  公开号：US20110281873A1

  公开（公告）日：2011-11-17

  Disclosed herein are pyrimidinyl compounds that are contemplated to be modulators of cystic fibrosis transmembrane regulators (CFTR), and methods of making and using same. Also provided are pharmaceutical compositions and methods of treating disorders associated with cystic fibrosis transmembrane regulators, such as airway inflammation, cystic fibrosis, and the like.

  本文披露了嘧啶基化合物，被认为是囊性纤维化跨膜调节器（CFTR）的调节剂，并提供了制备和使用它们的方法。还提供了药物组合物和治疗与囊性纤维化跨膜调节器相关的疾病的方法，例如气道炎症，囊性纤维化等。
• GUANIDINOBENZAMIDES AS MC4-R AGONISTS
  申请人：CHIRON CORPORATION

  公开号：EP1409468A2

  公开（公告）日：2004-04-21
• US5840908A
  申请人：——

  公开号：US5840908A

  公开（公告）日：1998-11-24